Navigation Links
VIVUS to Present at Two Upcoming Investor Conferences

MOUNTAIN VIEW, Calif., March 3 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that Timothy Morris, Chief Financial Officer, will present an overview of the company at two investment conferences during the month of March.

    The conference presentation schedule is as follows:

     Cowen and Company 30th Annual Health Care Conference
     March 10, 2010 at 9:30 a.m. ET
     The Boston Marriott Copley Place, Boston, MA

     Roth Capital Partners 22nd Annual OC Growth Stock
     March 16, 2010 at 12:00 p.m. PT
     The Ritz Carlton, Dana Point, CA

A live audio webcast and 30-day archive of the presentations will be available on VIVUS' website at


VIVUS is a biopharmaceutical company developing innovative, next- generation therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health. The company's lead product in clinical development, Qnexa(R), has completed phase 3 clinical trials for the treatment of obesity and an NDA has been filed and accepted by the FDA, with an action date of October 28, 2010. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor for the treatment of erectile dysfunction, and in phase 2 development of Luramist(TM) for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE(R) (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit


    VIVUS, Inc.
    Timothy E. Morris
    Chief Financial Officer

    Investor Relations:
    The Trout Group
    Brian Korb

    Media Relations:
    Pure Communications, Inc.
    Dan Budwick


Back to top



Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. VIVUS Reports Third Quarter 2009 Highlights and Financial Results
2. VIVUS Announces Positive Results From Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-Morbidities
3. VIVUS to Present at Four Upcoming Healthcare Conferences
4. VIVUS to Present at the Canaccord Adams 29th Annual Global Growth Conference
5. VIVUS to Present at the Needham and Company Life Sciences Conference
6. Data on VIVUS Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting
7. VIVUS Reports First Quarter 2009 Financial Results and Highlights
8. PDI to Present at the ROTH Capital Partners 22nd Annual OC Growth Stock Conference
9. Nutrastar International, Inc. to Present at the 2010 Rodman & Renshaw Annual China Investment Conference in Beijing
10. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
11. Creating a Better Health Ecosystem Focus of Presentation by Aleres Dr. Gordon Norman at Population Health & Disease Management Colloquium
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... , President and CEO of Neurocrine Biosciences, will be ... in New York . ... the website approximately 5 minutes prior to the presentation ... of the presentation will be available on the website ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... uBiome, were featured on AngelList early in their initial angel funding process. Now, ... syndicate for individuals looking to make early stage investments in the microbiome space. ...
(Date:11/24/2015)... , Nov. 24, 2015 /CNW/ - iCo Therapeutics ("iCo" ... reported financial results for the quarter ended September ... in Canadian dollars and presented under International Financial ... States ," said Andrew Rae , ... regarding iCo-008 are not only value enriching for ...
(Date:11/24/2015)... -- --> --> ... Market by Product & Services (Primer, Probe, Custom Oligos, ... End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) - Global ... expected to reach USD 1,918.6 Million by 2020 from ... 10.1% during the forecast period. Browse 183 ...
Breaking Biology Technology:
(Date:11/18/2015)... New York , November 18, 2015 ... Market Research has published a new market report titled ... Growth, Trends, and Forecast, 2015 - 2021. According to the ... in 2014 and is anticipated to reach US$29.1 bn ... to 2021. North America ...
(Date:11/17/2015)... 17, 2015 Paris ... --> Paris , qui s,est ... DERMALOG, le leader de l,innovation biométrique, a inventé le ... et empreintes sur la même surface de balayage. Jusqu,ici, ... l,autre pour les empreintes digitales. Désormais, un seul scanner ...
(Date:11/17/2015)... Mass. , Nov. 17, 2015 Pressure ... leader in the development and sale of broadly enabling, ... worldwide life sciences industry, today announced it has received ... its $5 million Private Placement (the "Offering"), increasing the ... $4,025,000.  One or more additional closings are expected in ...
Breaking Biology News(10 mins):